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Abstract
Epidemiological studies have reported a higher incidence of rare disorders involving imprinted genes among children
conceived using assisted reproductive technology (ART), suggesting that ART procedures may be disruptive to imprinted
gene methylation patterns. We examined intra- and inter-individual variation in DNA methylation at the differentially
methylated regions (DMRs) of the IGF2/H19 and IGF2R loci in a population of children conceived in vitro or in vivo. We found
substantial variation in allele-specific methylation at both loci in both groups. Aberrant methylation of the maternal IGF2/
H19 DMR was more common in the in vitro group, and the overall variance was also significantly greater in the in vitro
group. We estimated the number of trophoblast stem cells in each group based on approximation of the variance of the
binomial distribution of IGF2/H19 methylation ratios, as well as the distribution of X chromosome inactivation scores in
placenta. Both of these independent measures indicated that placentas of the in vitro group were derived from fewer stem
cells than the in vivo conceived group. Both IGF2 and H19 mRNAs were significantly lower in placenta from the in vitro
group. Although average birth weight was lower in the in vitro group, we found no correlation between birth weight and
IGF2 or IGF2R transcript levels or the ratio of IGF2/IGF2R transcript levels. Our results show that in vitro conception is
associated with aberrant methylation patterns at the IGF2/H19 locus. However, very little of the inter- or intra-individual
variation in H19 or IGF2 mRNA levels can be explained by differences in maternal DMR DNA methylation, in contrast to the
expectations of current transcriptional imprinting models. Extraembryonic tissues of embryos cultured in vitro appear to be
derived from fewer trophoblast stem cells. It is possible that this developmental difference has an effect on placental and
fetal growth.
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Introduction
Several epidemiological studies have reported a higher inci-
dence of rare disorders involving imprinted genes (Angelman
syndrome [1–3] and Beckwith-Wiedemann syndrome [4–8])
among children conceived using assisted reproductive technologies
(ART). Studies on imprinted gene expression and parental allele-
specific DNA methylation in animal models have also suggested
that epigenetic marks may be altered by treatments and
procedures commonly employed in ART (ovarian stimulation,
egg retrieval, in vitro fertilization, intracytoplasmic sperm injection,
preimplantation embryo culture, embryo transfer) [9–13].
CpG sites in differentially methylated regions (DMRs) of
imprinted genes are methylated on the allele contributed by one
parent and unmethylated on the allele contributed by the other.
This pattern of differential allelic methylation is established during
male and female gametogenesis [14,15] and the differences are
maintained after fertilization such that cells from most somatic
tissues are expected to exhibit the same parental allele-specific
methylation pattern [16,17]. However, if ART treatments and
procedures in the human are disruptive to imprinted gene
methylation patterns, as they are in the mouse [18], one might
predict that alterations could occur in some cells of the early
embryo but not in others, resulting in individuals who were mosaic
to varying degrees for loss or relaxation of proper imprinted allelic
methylation. In addition, different degrees of relaxation of allele-
specific methylation could be observed between different tissues of
the same individual, depending on when the disruption occurred
during development.
One of the loci shown to be susceptible to alteration of
epigenetic modifications by in vitro culture and ovarian stimulation
in the mouse is Igf2/H19 [11,13,19–23]. Because IGF2 is an
important placental growth factor and one of the phenotypes most
strongly associated with human ART procedures is low birth
PLoS Genetics | www.plosgenetics.org 1 July 2010 | Volume 6 | Issue 7 | e1001033weight, we reasoned that the human IGF2/H19 locus might also
be susceptible during ART treatments and procedures. We
compared parental allele-specific methylation between children
conceived in vitro or in vivo at the DMR that functions as an imprint
control region (ICR) at IGF2/H19 [24,25] and also at an IGF2
receptor (IGF2R) DMR [26,27]. We examined a sample of cord
blood, a section of umbilical cord and five sections of placenta in
each child for abnormal methylation of maternal alleles at the
IGF2/H19 ICR/DMR and for abnormal methylation of paternal
alleles at the IGF2R DMR [28]. Under our null hypothesis, little
variation in parental allele-specific methylation was expected
within an individual, or between individuals, because the
methylation status of each CpG site in the DMR is set in the
gametes [29] and faithful replication of this status during
development is expected to result in the same allelic methylation
ratio in each individual and in each tissue. We also measured
steady-state IGF2, H19 and IGF2R transcript levels to determine
whether mRNA levels were correlated with abnormal allelic
methylation ratio or birth weight. To our knowledge, this is the
first study to examine intra-individual variation in epigenetic
markings in children conceived using assisted reproduction.
Results
Intra- and Inter-Individual Variation in DNA Methylation
at the IGF2/H19 DMR
We investigated intra- and inter-individual variation in allele-
specific methylation at the IGF2/H19 DMR. We measured the
relative level of CpG methylation on maternal and paternal alleles
at this locus in cord blood, cord and five sections of placenta taken
from a population of children conceived either in vitro or in vivo.
The imprinted IGF2/H19 DMR is located between the IGF2
and H19 genes and is normally methylated on only the paternal
allele [24,30]. We used a single nucleotide polymorphism (a C/T
SNP at a CfoI site) to identify informative (heterozygous)
individuals and a methylation-sensitive restriction endonuclease
(MluI) to determine the methylation status of a specific CpG site
within the DMR, as described previously [28]. Methylation at the
MluI site, and an adjacent MaeII site, have been shown previously
to be characteristic of the methylation at surrounding CpGs by
bisulfite sequencing (Fig. 7 in Sandovici et al., 2003) [28]. We
identified 45 in vitro and 56 in vivo individuals who were informative
and for whom DNA was available from cord blood, cord and five
sections of placenta.
Because previous studies have indicated that loss or relaxation of
imprinting is a quantitative trait [31,32], we measured the ratio
between DNA methylation levels on maternal and paternal (M/P)
alleles as an indicator of imprinting status. A ratio of zero
corresponds to exclusive methylation of the MluI site on the
paternal allele, while a ratio of one signifies methylation of this site
on an equal number of maternal and paternal alleles (n.b.:
Although we have not determined the parental origin of each allele
in the present study because DNA was not available from parents,
we have shown previously that the less methylated allele was
maternal in all 163 individuals for whom we were able to
determine parental origin by pedigree analysis [28]. We therefore
assume that the less methylated allele is maternal in the population
examined here, also.) In the case of controls, no uncleaved C
alleles were detected in any C/C homozygous individuals,
indicating that CfoI cleaved the ‘‘hot-stop’’ PCR products with
.99% efficiency [33].
Figure 1 shows the distribution of M/P methylation ratios
observed from 56 informative in vivo (Figure 1A) and 45
informative in vitro (Figure 1B) individuals. The M/P ratios were
measured for cord blood, cord and five sections of placenta from
each informative individual. The data are represented as a series of
symbols on a vertical line, ranked from individuals showing the
greatest range of variation on the left side of the graph to
individuals showing the least range of variation on the right side of
the graph. The distribution of individual M/P methylation ratios
in cord blood (red circles in Figure 1) shows that the great majority
of informative individuals have ,15% methylation on the
maternal allele in both groups. Approximately 8% of the
population examined here has $15% of methylation of CpG
sites on the maternal allele in cord blood. These findings are
similar to those reported previously by Sandovici et al. (2003) for
M/P methylation ratios measured in peripheral blood samples
from the CEPH families [28]. The distribution of individual M/P
methylation ratios in cord showed a similar pattern to that
observed in cord blood (Figure 1), while the five sections of
placenta taken from each individual showed a broad range of
intra-individual variation in M/P methylation ratios.
When individual tissues are compared, both M/P ratio mean
and variance are greater in the in vitro group in each tissue,
although two of these comparisons (cord blood means, in which
the fewest samples are compared between the two groups, and
placenta variance, in which the greatest range of variation is
observed) do not reach statistical significance (Table 1). However,
because the a priori expectation for the mean M/P methylation
ratio of the IGF2/H19 DMR is near zero, independent of the
embryonic origin of the tissue (because the methylation status of
maternal and paternal DMR alleles is assumed to be determined
in the gametes and to escape the genome wide demethylation/
remethylation that occurs in preimplantation embryos) [16], it is
not inappropriate to combine all samples in each group to
determine whether the two groups differ in mean M/P ratio and
whether the groups have equal variance. When samples from all
tissues are combined, both allele-specific methylation ratio mean
and variance are significantly greater in the in vitro group
(P=0.0001 and P=0.0006, respectively, Table 1). The fact that
the intra-individual variation in M/P ratios is also greater in the in
vitro group may be seen, simply, by comparing the fraction of
individuals in each group in which all samples have M/P ratios
below any arbitrarily chosen value. For example, only 31% of in
Author Summary
We have screened a population of children conceived in
vitro for epigenetic alterations at two loci that carry parent-
of-origin specific methylation marks. We made the
observation that epigenetic variability was greater in
extraembryonic tissues than embryonic tissues in both
groups, as has also been demonstrated in the mouse. The
greater level of intra-individual variation in extraembryonic
tissues of the in vitro group appears to result from these
embryos having fewer trophoblast stem cells. We also
made the unexpected observation that variability in
parental origin-dependent epigenetic marking was poorly
correlated with gene expression. In fact, there is such a
high level of inter-individual variation in IGF2 transcript
level that the presumed half-fold reduction in IGF2 mRNA
accounted for by proper transcriptional imprinting versus
complete loss of imprinting would account for less than
5% of the total population variance. Given this level of
variability in the expression of an imprinted gene, the
presumed operation of ‘‘parental conflict’’ as the selective
force acting to maintain imprinted gene expression at the
IGF2/H19 locus in the human should be revisited.
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blood, cord and all five sections of placenta while 46% of in vivo
individuals (26/56) are below this threshold.
Greater Intra-Individual Variance in Placenta M/P Ratios Is
Associated with Fewer Trophoblast Stem Cells
One mechanism by which greater variance in an epigenetic
character may occur is through a sampling effect that depends on
the number of stem cell progenitors that give rise to a particular
tissue; the fewer the number of stem cells, the greater the variance.
Because much of the difference in variance observed between the
two groups occurs as a result of intra-individual differences in
umbilical cord and placenta samples, we estimated the number of
trophoblast stem cells that give rise to the placenta in each group
by comparing the distribution of X-inactivation scores in females
from each comparison group [34,35] and by comparing the
distribution of M/P IGF2/H19 methylation ratios from Figure 1.
We note that the assay used in each case amounts to a simple yes/
Figure 1. Allele-specific methylation at the IGF2/H19 DMR. (A) 56 informative in vivo individuals, and (B) 45 informative in vitro individuals. M/P
represents the DNA methylation ratio between maternal and paternal alleles (see text). Each individual is represented as vertical data-set of M/P ratios
from cord blood, cord and five sections of placenta. Individuals were ranked based on the degree of scatter (intra-individual variation) observed.
doi:10.1371/journal.pgen.1001033.g001
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methylated (in which case it gives a signal) or not (in which case it
does not)’’, each of which is expected to yield a ‘‘success’’ (the
DNA molecule in question is methylated) with probability ‘‘p’’
(p=0.5 in the case of which X chromosome is inactivated and
p=0.1 in the case of methylation of the maternal IGF2/H19
DMR, see below) or a failure with probability ‘‘q’’ (which is equal
to 1-p).
The number of trophoblast stem cells may be estimated from
the distribution of X-inactivation scores by comparing the actual
distribution of X-inactivation scores with the distribution estimat-
ed from the variance of the binomial distribution (pq/N), setting
the probability that either allele is methylated (p or q) to 0.5 and
generating the distribution for different values of N (number of
stem cells) [34,35]. We determined the X-inactivation score
distribution for each group (using DNA samples from five sections
of placenta from 50 in vitro and 54 in vivo females) by comparing
allele-specific methylation at HpaII sites adjacent to the CAG
trinucleotide repeat in the highly polymorphic Androgen Receptor
locus (AR) [36]. The closest fit to the distribution of X-inactivation
scores in placenta in children conceived in vitro corresponds to nine
trophoblast stem cells and the closest fit in children conceived in
vivo corresponds to 11 trophoblast stem cells (Table 2).
We additionally estimated the number of trophoblast stem cells
in each group by comparing the distribution of M/P IGF2/H19
DMR methylation ratios (Figure 1) from the two comparison
groups, using 0.1 and 0.9 as values for p and q (these values were
selected based on the observation that ,10% of individuals have
significant methylation on the maternal DMR while ,90% have
very few cells carrying maternal DMR methylation [28]. These
values are also in close agreement with the probability that any
maternal DMR DNA molecule is methylated (placenta in vivo
mean =0.0801, in vitro mean =0.1017, Table 1). Using these
parameters, the closest fit to the distribution of M/P ratios in
placenta in children conceived in vitro corresponds to eight
trophoblast stem cells and the closest fit in children conceived in
vivo corresponds to 10 trophoblast stem cells (Table 2).
Overall, these very similar independent estimates of between-
group epigenetic variation (n.b.: not only are the two loci examined
on different chromosomes but many of the individuals in the X-
inactivation groups, composed of only females, and the IGF2/H19
groups were different) are consistent with the prediction that
overall greater variance in M/P IGF2/H19 DMR methylation
ratios in the in vitro group is associated with fewer trophoblast stem
cells.
Analyses of IGF2/H19 DMR Methylation in Placenta by
Pyrosequencing
Because the methylation-sensitive restriction endonuclease assay
used to generate the data shown in Figure 1 provides a ratio of
maternal alleles at which MluI sites are methylated to paternal
alleles at which MluI sites are methylated rather than an absolute
fraction of all alleles, we also assayed DNA methylation at the
IGF2/H19 DMR by bisulfite pyrosequencing. The assay we used
quantifies the methylation status of five CpGs in the IGF2/H19
DMR that are adjacent to the CpG queried in the MluI assay. If
an M/P ratio greater than zero (Figure 1) represents methylation
of maternal alleles in addition to methylation of DMRs on all
paternal alleles, then the CpG sites in these samples/individuals
should be methylated on greater than 50% of molecules assayed
by bisulfite pyrosequencing (i.e. all paternal alleles plus some
fraction of maternal alleles). The placenta samples with M/P ratios
greater than zero show greater than 50% methylation at all five
CpGs in almost all cases (Figure 2) by bisulfite pyrosequencing,
indicating that both the methylation-sensitive restriction endonu-
clease assay and the bisulfite pyrosequencing assay are measuring
gain of methylation on maternal alleles, as has also been reported
in the mouse [19,22,23].
Allele-Specific Expression of IGF2/H19 Is Not Disrupted by
Bi-Allelic Methylation of the DMR
The current model for imprinted transcriptional control of
IGF2/H19 correlates methylation at the ICR/DMR with an
inability to bind CTCF, transcriptional silencing of H19 and
transcriptional activation of IGF2 [37,38]. Because our analysis of
Table 1. Intra- and inter-individual variation in DNA
methylation at the IGF2/H19 DMR.
Tissue Group
a Mean Variance Means
b (P) Variances (P)
Cord
Blood
In vitro 0.0617 0.0135 0.2546 0.0001
In vivo 0.0416 0.0041
Cord In vitro 0.0993 0.0083 0.0075 ,0.0001
In vivo 0.0550 0.0023
Placenta In vitro 0.1017 0.0111 0.0059 0.0620
In vivo 0.0801 0.0091
Total In vitro 0.0970 0.0110 0.0001 0.0006
In vivo 0.0716 0.0077
aM/P methylation ratios measured in cord blood, cord, and five sections of
placenta tissue from 45 informative in vitro individuals and 56 informative in
vivo individuals.
bWilcoxon Rank Sums Test (P#0.05 considered significant).
doi:10.1371/journal.pgen.1001033.t001
Table 2. Determining number of stem cells by approximating the variance of binomial distribution of X-inactivation and M/P IGF2/
H19 methylation ratio results.
Assay Tissue Group Mean SD
c or Variance
d Number of stem cells
X-inactivation
a Placenta In vitro 0.4775 0.1637
c 9.33
In vivo 0.4824 0.1502
c 11.09
IGF2/H19 DMR methylation
b Placenta In vitro 0.1017 0.0111
d 8.15
In vivo 0.0801 0.0091
d 9.90
aX-inactivation ratios were measured in five sections of placenta from 50 in vitro and 54 in vivo females using the HUMARA PCR assay.
bAllele-specific methylation ratios at the IGF2/H19 DMR were measured in five sections of placenta from 45 informative in vitro individuals and 56 informative in vivo
individuals.
doi:10.1371/journal.pgen.1001033.t002
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DMRs are methylated, we examined mRNA expression in
individuals with varying levels of bi-allelic DMR methylation, for
the presence of bi-allelic transcripts of IGF2 and H19. We assayed
individuals who were informative for an ApaI polymorphism (in
exon 9) for the presence of transcripts from both IGF2 alleles [32].
We also assayed individuals who were informative for an RsaI
polymorphism (in exon 5) for the presence of transcripts from both
H19 alleles [39], which would be expected to occur if paternal
DMRs became demethylated.
Although we detected minor amounts of presumed maternal
IGF2 mRNA in several individuals, there was no correlation
between maternal DMR methylation and amount of transcript
from the maternal allele (Table 3). We also observed only small
amounts of presumed paternal allele expression of H19 mRNA,
which suggested that there was no loss of methylation on paternal
alleles in these samples (Table 3), also consistent with the overall
greater than 50% methylation observed by pyrosequencing
(Figure 2).
Intra-Individual Variation in DNA Methylation at the
IGF2R DMR
We investigated intra-individual variation in allele-specific
methylation at an IGF2R DMR we have also examined previously
[28]. The rationale for examining allele-specific methylation at this
non-transcriptionally imprinted locus is that this locus may be a
more sensitive reporter of any disruption in CpG site methylation
by environmental factors because such changes are not predicted
Figure 2. Pyrosequencing methylation at the IGF2/H19 DMR in placenta. (A) 31 in vivo individuals, and (B) 26 in vitro individuals. The
methylation results at each CpG site for each individual are represented by a horizontal series of symbols. All but a few of the CpGs show methylation
levels of 50% or higher, which is in concordance with our findings of gain of methylation on the maternal allele (M/P $0.15 in placenta, Figure 1).
doi:10.1371/journal.pgen.1001033.g002
Epigenetic Variation in Assisted Reproduction
PLoS Genetics | www.plosgenetics.org 5 July 2010 | Volume 6 | Issue 7 | e1001033to affect transcription and are less likely to be selected against. The
relative level of CpG methylation on paternal and maternal alleles
at this locus was measured in cord blood, cord and five sections of
placenta taken from populations of children conceived either in
vitro or in vivo. The less methylated allele is assumed to be paternal
because we found no individuals in which the paternal allele was
more methylated than the maternal allele in 112 informative
individuals for whom allelic inheritance could be confirmed by
pedigree analysis [28].
The parental origin-specifically methylated IGF2R DMR is located
in the second intron of IGF2R and is normally methylated on the
maternal allele. Although the human IGF2R gene is transcribed from
both alleles [40] differential methylation of maternal and paternal
alleles is maintained in the human, as it is in the mouse [26] and a
small fraction of the human population may have transcriptional
imprinting of IGF2R [27]. We used a single nucleotide polymorphism
within an MspI site to identify maternal and paternal alleles of
informative (heterozygous) individuals and a methylation-sensitive
restriction endonuclease (NotI) to determine the methylation status of
a specific CpG site within the DMR [28]. We identified 28 in vitro and
27 in vivo individuals who were informative and assayed allele-specific
methylation as described previously [28].
We calculated the ratio between the DNA methylation levels on
paternal and maternal (P/M) alleles as an indicator of methylation
imprint status. A ratio of zero corresponds to exclusive methylation
of the NotI site on the maternal allele, while a ratio of one signifies
methylation of this site on an equal number of paternal and
maternal alleles. In the case of controls, no uncleaved C alleles
were detected in any C/C homozygous individuals, indicating that
MspI cleaved the PCR products with .99% efficiency.
Although preferential methylation of the presumed maternal
allele was observed in almost all individuals (Figure 3), the
distribution of paternal/maternal (P/M) methylation ratios at the
IGF2R DMR in cord blood and cord showed that most individuals
have an easily measurable level of methylation at the CpG within
the NotI cleavage site on the presumed paternal allele (P/M.0.1,
Figure 3), as has also been observed previously in peripheral blood
from the CEPH families [28].
In cord blood, only 34% of the total population has low levels of
methylation on the paternal allele (P/M allele ratios of ,0.1) while
a very small fraction of individuals (2%) have P/M allelic
methylation ratios greater than 0.5. The distribution of individual
P/M methylation ratios in cord (Figure 3) also showed a similar
pattern to what was observed in cord blood. However, results from
five placenta sections taken from the same individuals showed
nearly complete loss of the methylation imprint (i.e. P/M ratios
close to 1) at this locus in samples from multiple individuals in both
in vitro and in vivo groups (Figure 3).
We found no difference in mean P/M ratios in cord blood, cord
or placenta between the in vitro and in vivo groups, either comparing
individual tissue types or combining all samples (Table 4). Cord
blood allele-specific methylation ratio variance was greater in the
in vitro group (P=0.0016) but we did not attempt to calculate a
cord blood stem cell number comparison because of the small
number of samples on which to model the distribution. There was
no significant difference in the population variance in the in vitro
group in cord or placenta, although the presence of a substantial
fraction of samples in both groups for which nearly complete loss
of the methylation imprint (P/M.0.9) was observed is likely to
affect our ability to distinguish such a difference.
IGF2, H19, and IGF2R Steady-State mRNA Levels
We measured steady-state IGF2, H19 and IGF2R mRNA levels
in cord blood and placenta from children conceived in vitro or in
vivo (Table 5, Figure 4). In addition to the children who were
informative for allele specific DMR methylation (Figure 1 and
Figure 3), we also measured mRNA levels in the children who
were not informative. Mean cord blood IGF2R mRNA levels were
significantly lower in the in vitro group (fold change =0.61,
P=0.0039). Mean placental IGF2 and H19 mRNA levels were
also significantly lower in the in vitro group (fold change =0.52,
P,0.0001, and fold change =0.72, P=0.0193, respectively).
Discussion
We have examined intra- and inter-individual variation in DNA
methylation at the differentially methylated regions (DMRs) of the
IGF2/H19 and IGF2R loci in cord blood, cord and five sections of
placenta from a population of children conceived in vitro or in vivo.
Although a significant fraction of individuals in both groups do
appear to maintain the IGF2/H19 methylation imprint ‘‘correct-
ly’’, with M/P ratios of ,0.1 (93.6% of peripheral blood samples
are below this M/P ratio, Sandovici et al., 2003) [28], we found
substantial intra-individual and inter-individual variation in allele-
specific methylation in both groups in all three tissues: 8/46
individuals in the in vivo group and 7/40 individuals in the in vitro
group have cord blood M/P ratios above this level (n.b. of the 56
informative in vivo and 45 informative in vitro individuals shown in
Figure 1, cord blood samples were unavailable for 10 of the in vivo
and five of the in vitro children). The acquisition of CpG
methylation on only a fraction of maternal IGF2/H19 DMRs in
so many individuals suggests that there is extensive population
level variation in the time at which methylation imprints become
set during development, especially in extraembryonic lineages.
Table 3. Allelic-specific expression of IGF2 and H19 in human
placenta.
Tissue Group
Maternal/Paternal
Ratio
a
IGF2 Maternal
Expression
b
H19 Paternal
Expression
Placenta In vitro 0.016 2.9%
0.020 6.9%
0.023 7.0%
0.027 1.6%
0.032 15.8%
0.055 2.5%
0.058 1.9%
0.068 1.2%
0.156 1.6%
0.184 1.0%
0.472 0.8%
In vivo 0.004 2.8%
0.027 2.6%
0.088 3.0%
0.187 2.1%
0.236 5.5%
0.307 8.8%
aDNA methylation levels on maternal and paternal (M/P) alleles (a ratio of zero
corresponds to exclusive methylation of the MluI site on the paternal allele, while
a ratio of one signifies methylation of this site on an equal number of maternal
and paternal alleles).
bThe threshold for scoring loss of imprinting for IGF2 was a ratio of less than 3:1
between the more-abundant and less abundant alleles [32].
doi:10.1371/journal.pgen.1001033.t003
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individual variation in P/M methylation ratios at an IGF2R DMR.
Very few individuals (one in the in vivo group, two in the in vitro
group) maintained this imprint ‘‘correctly’’ in all samples (even if
the threshold for ‘‘correctly’’ is reduced to P/M ratios ,0.2) and
the discrepancy between maintaining the imprint in embryonic
and extraembryonic tissue is even more pronounced (Figure 3).
The observation of greater epigenetic variation in extraembryonic
than in embryonic tissues is consistent with observations at a
number of imprinted loci, including IGF2/H19, in the mouse [11].
We believe this is the first time this observation has been made in
the human. Parental allele-specific mean methylation ratios at the
IGF2/H19 DMR were greater in the in vitro group, indicating
acquisition of methylation on maternal alleles. This finding is
consistent with observations made at Igf2/H19 in the mouse [23].
The total variance in M/P ratio at IGF2/H19 was significantly
greater in cord blood and cord from the in vitro group, with a
suggestive P-value (0.0620) for placenta. These findings indicate
an association between ART and the magnitude of the variance
in parental allele-specific methylation patterns. The mechanism
by which greater variance might be created in the in vitro group is
unclear but could be related to the number of trophoblast stem
cells that give rise to the placenta in each group. If fewer
trophoblast stem cells give rise to the placenta in the in vitro
group, one expects greater intra-individual variation in somat-
ically heritable epigenetic marks if the population of stem cells
contains cells with more than one epigenetic state (i.e. IGF2/H19
DMRs that are methylated only on the paternal allele in some
cells and methylated on both maternal and paternal alleles in
others).
Figure 3. Allele-specific methylation at the IGF2R DMR. (A) 27 informative in vivo individuals, and (B) 28 informative in vitro individuals. P/M
represents the DNA methylation ratio between paternal and maternal alleles (see text). Each individual is represented as vertical data-set of P/M ratios
from cord blood, cord and five sections of placenta. Individuals were ranked based on the degree of scatter (intra-individual variation) observed.
doi:10.1371/journal.pgen.1001033.g003
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chromosome inactivation ratios in five sections of placenta in
females from the in vitro (50 individuals) and in vivo groups (54
individuals) in order to estimate the number of trophoblast stem
cells that give rise to the placenta in each group. The closest fit to
the in vitro X-inactivation distribution corresponds to nine
trophoblast stem cells while the closest fit to the in vivo distribution
corresponds to 11 trophoblast stem cells. We additionally
estimated the number of trophoblast stem cells in each group by
comparing the distribution of M/P IGF2/H19 DMR methylation
ratios from the two comparison groups. The closest fit to the
distribution of M/P ratios in placenta in children conceived in vitro
corresponds to eight trophoblast stem cells and the closest fit in
children conceived in vivo corresponds to 10 trophoblast stem cells.
Overall, these estimates of between group intra-individual
epigenetic variation are consistent with the prediction that overall
greater variance in M/P IGF2/H19 DMR methylation ratios in
the in vitro group is associated with fewer trophoblast stem cells.
Although our statistical estimates of the number of trophoblast
stem cells is imprecise, it gives one some confidence that similar
absolute numbers are obtained (Table 2) from estimates of
epigenetic variance at two different loci, examining different
individuals with each assay. Whether the calculated difference in
number of trophoblast stem cells reflects designation of trophoblast
stem cells at an earlier stage of development (when fewer cells are
present in the embryos) or whether embryos from the in vitro group
have fewer cells than in vivo embryos at comparable stages cannot
be determined from these data, however, previous reports suggest
that in vitro mouse embryos may contain fewer cells than in vivo
embryos at the same developmental time [41]. Our approach of
using epigenetic variance to calculate the number of trophoblast
stem cells is, for obvious reasons, the only opportunity for
estimating this number in the human because direct comparisons
of cell numbers in in vitro and in vivo embryos is not possible.
We note that while we have uncovered locus-specific differences
in the level of epigenetic variation in children conceived in vitro,w e
cannot distinguish whether the differences are due to some aspect
of the assisted reproduction process or is related to the underlying
infertility. In fact, the characteristic of epigenetic variance, itself,
may be under genetic control and may also be influenced by the
environment [42]. Greater variance in trait value, even without
changes in trait mean, is predicted to have a substantial positive
effect on fitness in a changing environment [42]. In this regard, we
note that in vitro conception is associated with at least two changes
of environment (hormonal stimulation, retrieval of ova from the
maternal environment to fertilization and culture in vitro, followed
by return to the maternal environment). A larger-scale epigenetic
screen is required in order to determine whether there is a
tendency for in vitro conception to be associated with overall
increased variance of epigenetic marks.
Several observations are noteworthy about the steady-state
mRNA levels measured for IGF2 in placenta. First, IGF2 mRNA
levels in placentas from in vitro conceived children, as a group, were
approximately half of what was observed in children conceived in
vivo. This observation is consistent with experiments demonstrating
reduced Igf2 mRNA levels in placentas from mouse embryos
subject to in vitro manipulations [20]. Second, reduction in IGF2
mRNA levels in the human placentas does not occur in
conjunction with loss of methylation at the paternal DMR, as
expected if transcript levels are controlled by genomic imprinting
alone. Furthermore, we did not observe that increased levels of
methylation at the maternal DMR induced a coordinate level of
transcription from the maternal IGF2 allele. In fact, given that
IGF2 transcript levels vary by more than an order of magnitude
between individuals (Figure 4) and almost by that much between
samples within a single placenta (Figure S1), the mechanism by
which natural selection might act in a population, on a process
whose postulated design is to reduce transcription by half (from
two alleles to one) is unclear. Along these same lines, we observed
no correlation between birth weight and IGF2 transcript levels in
either placenta or cord blood, whether or not birth weights were
corrected for gestational age (Figure S2). This last observation was
not completely unexpected, as several laboratories have failed to
observe a correlation between IGF2 mRNA levels and birth
weight [43–45]. In this regard, it is likely that epigenetic marking
of genes according to parental origin plays an important role in
other processes associated with reproduction and the formation of
gametes, such as chromosome pairing and recombination [46–49].
The selective force for the maintenance of imprinting in these
processes is both direct (successful recombination is required for
successful gametogenesis) and related to reproductive success.
We also observed that mean steady-state levels of IGF2R
mRNA were lower in cord blood from the in vitro group. This
locus does not appear to be transcriptionally imprinted in most
humans [40,50], although the preferential methylation of only
one parent’s allele (the maternal) is conserved [26,27]. Although
not transcriptionally imprinted, we did note an inverse correla-
Table 4. Intra- and inter-individual variation in DNA
methylation at the IGF2R DMR.
Tissue Group
a Mean Variance Means
b (P) Variances (P)
Cord Blood In vitro 0.1896 0.0305 0.6548 0.0016
In vivo 0.1401 0.0085
Cord In vitro 0.1803 0.0257 0.5716 0.3072
In vivo 0.1866 0.0210
Placenta In vitro 0.6199 0.0656 0.9782 0.4463
In vivo 0.6263 0.0640
Total In vitro 0.5086 0.0918 0.6828 0.4483
In vivo 0.4960 0.0936
aP/M methylation ratios measured in cord blood, cord, and placenta tissue (5
sections) from 28 informative in vitro individuals and 27 informative in vivo
individuals.
bWilcoxon Rank Sums Test (P#0.05 considered significant).
doi:10.1371/journal.pgen.1001033.t004
Table 5. Differences in transcript level between in vitro and in
vivo groups.
Tissue Gene
No. individuals
(in vitro/in vivo)
Fold
change
a P
b
Cord Blood H19 73/118 0.88 0.8774
IGF2 77/116 1.03 0.5551
IGF2R 75/121 0.61 0.0039
Placenta H19 84/135 0.72 0.0193
IGF2 98/160 0.52 ,0.0001
IGF2R 97/148 1.18 0.2227
aFold change in in vitro conceived individuals compared with in vivo conceived
individuals, obtained using the DDCT method [62].
bStudent’s T-test (P#0.05 considered significant).
doi:10.1371/journal.pgen.1001033.t005
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PLoS Genetics | www.plosgenetics.org 8 July 2010 | Volume 6 | Issue 7 | e1001033Figure 4. Scatter plots showing mRNA transcript levels in the in vitro and in vivo populations. Each symbol represents the mRNA level in
one individual. (A) H19 in cord blood (in vitro n=73, in vivo n=118, fold change 0.88, P=0.8774), (B) IGF2 in cord blood (in vitro n=77, in vivo n=116,
fold change 1.03, P=0.5551), (C) IGF2R in cord blood (in vitro n=75, in vivo n=121, fold change 0.61, P=0.0039), (D) H19 in placenta (in vitro n=84, in
vivo n=135, fold change 0.72, P=0.0193), (E) IGF2 in placenta (in vitro n=98, in vivo n=160, fold change 0.52, P,0.0001), and (F) IGF2R in placenta (in
vitro n=97, in vivo n=148, fold change 1.18, P=0.2227).
doi:10.1371/journal.pgen.1001033.g004
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transcript level, indicating that ‘‘aberrant’’ methylation of the
‘‘incorrect’’, paternal allele does have a small effect (accounting
for ,10% of the variance, Figure S3). Lower IGF2R mRNA level
in the in vitro group is, on the face of it, in contrast to expectations.
If IGF2R is a receptor that acts as a ‘‘sink’’ for IGF2 [51,52], one
might expect children conceived in vitro to have higher levels of
IGF2R because they have a higher probability of low birth weight
[53]. In any case, we did not find any correlation between birth-
weight, IGF2 levels, IGF2R levels or IGF2/IGF2R ratios (Figure
S2).
Overall, our results indicate that epigenetic modifications at
IGF2/H19 and IGF2R are subject to frequent changes during early
development, especially in extraembryonic tissues. Although not
all of the epigenetic changes appear to be manifested as significant
differences in DNA methylation, conception in vitro is associated
with gene expression differences for all three genes in some tissues.
Whether the gene expression differences between in vitro and in vivo
groups are also a manifestation of what appears to be a smaller
number of trophoblast stem cells in children from the in vitro group
is a subject for future investigation.
Materials and Methods
Subjects
The cases/in vitro group are newborns conceived by assisted
reproductive technology at a single infertility treatment center so
that the clinical and laboratory procedures are uniform. The
parents of the control/in vivo group had no prior history of
infertility and the index pregnancy was achieved without medical
assistance, such as the use of infertility medications or treatments.
All the in vitro patients were stimulated with commercially available
gonadotrophin preparations. The embryo culture media and the
incubation parameters were all the same. The cases and controls
were matched with regards to maternal age, race and gestational
age (Table S1). Written, informed consent was obtained in
advance from the mother of each newborn (University of
Pennsylvania I.R.B. approved protocol no. 804530). A summary
of the assays used, number of individuals studied and the tissues
investigated is provided in Table S2.
Sample Collection
Cord blood, cord and placenta samples were collected from
each in vitro and in vivo newborn. All cord blood samples were
collected within 20 min of delivery. Tissue samples were stored at
4uC after delivery, and samples were collected within five hours of
delivery [54]. The umbilical cord was wiped with normal saline
and the cord vein was punctured with a 21G needle. Whole cord
blood (6–10 ml) was collected in lavender topped vacutainer tubes
at room temperature. The sample was shaken thoroughly to
prevent clotting as the tube contains EDTA, ethylenediaminetet-
raacetic acid. An aliquot (3–4 ml) of cord blood was transferred to
a 15 ml Falcon tube containing RNALater RNA Stabilization
Reagent (Ambion, USA), following the manufacturers guidelines,
to stabilize the RNA. The remaining cord blood in the lavender
topped vacutainer tubes was saved for blood DNA extraction. All
cord blood DNA and RNA samples were initially stored at 4uC,
and nucleic acid extractions were performed within 2–4 days of
collection.
Placental tissue (1.5–2.5 cm
3) was excised from the fetal surface
of the placenta and rinsed extensively with sterile saline solution to
minimize maternal blood contamination. Each placenta was
sampled from four quadrants and from directly behind the cord
insertion site (this sample was used for the RT-PCR and
pyrosequencing assays, as well as for the allele-specific methylation
assays). A segment of umbilical cord (2 cm) was cut and treated in
a similar fashion. Placental and cord tissue for RNA extraction
were chopped into small pieces (0.5 cm
3) and immersed in
RNALater RNA Stabilization Reagent (Ambion, USA), following
the manufacturers guidelines, as soon as possible after collection.
All tissue DNA and RNA samples were initially stored at 4uC, and
tissue digestion and nucleic acid extractions were performed
within 2–4 days of collection. Approximately 4–5 mg of tissue was
used for the DNA and RNA extraction procedures, and the
remaining tissue was stored at 280uC.
DNA and RNA Isolation
Cord blood DNA was isolated using the ArchivePure DNA
Blood Kit (Fisher Scientific Company, USA) following the
manufacturers guidelines. Tissue genomic DNA was extracted
using standard phenol-chloroform extraction methods. The
isolated DNA was dissolved in 10 mM TrisCl, pH 8.0, quantified
using a spectrophotometer and stored at 280uC until further use.
Cord blood RNA was isolated using the PerfectPure RNA Blood
Kit (Fisher Scientific Company, USA) following the manufacturers
guidelines.
Total cellular RNA was extracted from each tissue sample using
TRIzol Reagent (Invitrogen Corporation, USA), according to the
manufacturers instructions. The isolated RNA was dissolved in
Milli-Q water, quantified using a spectrophotometer and stored at
280uC until further use.
Parental Allele-Specific Methylation at IGF2/H19 and
IGF2R DMRs
There are many DMRs on chromosome 11, but the most
consistent observations indicating a role in the control of
transcription of the IGF2 and H19 genes involve a CpG island
located in a 5 kb region centromeric to the H19 gene, known as
the IGF2/H19 DMR [25]. CpG sites within this DMR on the
paternal allele are normally methylated, while those on the
maternal allele are normally unmethylated [30,55–58]. This
region also contains seven different binding sites for the CTCF
protein [38] and the methylation status of the sixth binding site
was found to be most consistently associated with the transcrip-
tional status of both IGF2 and H19 [24].
The upstream H19 sequence used in this study is available from
GenBank (accession number AF125183). Allele-specific methyla-
tion was investigated by screening the DNA samples for a C/T
polymorphism recognized by CfoI at the IGF2/H19 DMR (near
the sixth binding site for CTCF) [24]. After identifying maternal
and paternal alleles of heterozygous individuals, a methylation-
sensitive restriction endonuclease (MluI) was used to determine the
methylation status of specific CpG sites within the DMR. If all
paternal alleles are methylated and all maternal alleles are
unmethylated at these sites in a sample of genomic DNA, then
all maternal alleles should be cleaved by MluI while all paternal
alleles will remain uncleaved. Amplification of the region by PCR
using primers that flank the MluI site should amplify only paternal
alleles (identified by post-PCR cleavage with CfoI). Amplification of
maternal alleles indicates resistance to cleavage by MluI. This may
occur as a result of methylation of the CpG site within the MluI
recognition sequence (the principle upon which the assay is based),
mutation of the MluI site or technical artifact. The latter two
possibilities may be distinguished from the first by DNA
sequencing, assay reproducibility and use of additional methyla-
tion-sensitive restriction endonucleases.
The IGF2R DMR is located in the second intron of IGF2R and
is normally methylated on the maternal allele. The sequence of
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Allele-specific methylation at the IGF2R DMR was investigated by
screening the DNA for a C/T polymorphism recognized by MspI.
After identifying maternal and paternal alleles of heterozygous
individuals, a methylation-sensitive restriction endonuclease (NotI)
was used to determine the methylation status of specific CpG sites
within the DMR.
Genomic DNA (100 ng) from informative individuals was
digested overnight at 37uC with an excess of a methyl-sensitive
restriction endonuclease: MluI and NotI for the IGF2/H19 and
IGF2R DMRs, respectively. Control individuals who were
homozygous for C alleles and homozygous for T alleles were also
analyzed in each experiment.
After digestion, the enzymes were denatured and the digested
DNA was amplified in a hot-stop PCR assay using the following
primers: IGF2-F 59-GAGATGGGAGGAGATACTAGG-39 and
IGF2-R 59-GTCAGTTCAGTAAAAGGCTGG-39 for the IGF2/
H19 DMR, and IGF2R-F 59-GGCCGAGGCCTGGCATG-
TTGG -39 and IGF2R-R 59-TGGGGAAGCGCGAGAGGCC-
TAGG-39 for the IGF2R DMR. After 30 cycles at 94uC for 30 s,
50uC for 30 s (IGF2/H19)o r6 3 uC for 30 s (IGF2R), and 72uC for
1 min, we added 3 mCi a-
32P dCTP for one additional cycle and a
final elongation step (72uC for 7 min). PCR products were then
digested overnight at 37uC with the enzyme used for identifying the
parental origin of the alleles (CfoI for IGF2/H19 and MspI for
IGF2R). The samples were separated on denaturing 5% polyacryl-
amide gels and the intensity of the bands (alleles) were quantified
using a PhosphoImage Reader FLA 5000 (FUJIFILM Medical
Systems USA, Inc.).
Analyses of IGF2/H19 DMR Methylation by
Pyrosequencing
We used a custom pyrosequencing assay for the IGF2/H19
DMR (NCBI36:11,2019856-2019740) which included five CpGs.
Genomic DNA (500 ng per sample) was bisulfite treated using EZ
Gold DNA Methylation Kit (Zymo Research, USA) following the
manufacturers protocol.
Bisulfite treated DNA was used for generating PCR amplified
templates for pyrosequencing. The PCR primer sequences were:
forward 59- GGGGTTATTTGGGAATAGG-39 and biotin
labeled reverse, 59- CCAAACCATAACACTAAAACCCTC-39.
The PCR reaction (30 ml) was following: 25 ng of bisulfite DNA,
0.75 U HotStar Taq Polymerase (Qiagen, USA), 1X PCR buffer,
3 mM MgCl2, 200 mM of each dNTPs, 6 pmol forward primer
and 6 pmol reverse primer. Recommended PCR cycling
conditions were: 95uC for 15 min; 45 cycles (95uC for 30 s;
60uC for 30 s; 72uC for 30 s); 72uC for 5 min. The biotinylated
PCR product (10 ml) was used for each sequencing assay with the
following sequencing primer: 59- GAATAGGATATTTATAG-
GAG-39. Pyrosequencing was done using the PSQ96HS system
according to standard procedures using Pyro Gold Reagent kits
(Biotage, Sweden). Methylation was quantified using Pyro Q-CpG
Software (Biotage, Sweden), which calculates the ratio of
converted C’s (T’s) to unconverted C’s at each CpG and expresses
this as a percentage methylation.
Quantitative Real-Time RT-PCR
First-strand cDNA was obtained using SuperScript III Reverse
Transcriptase (RT) (Invitrogen Corporation, USA). To produce
cDNA from total RNA, a mixture containing 0.5–1 mg extracted
total RNA, 0.5 mg oligo(dT)18 primer and 1 ml dNTP mix
(10 mM each) in a final 13 ml reaction volume was heated to 65uC
for 5 min, cooled down on ice for 1 min, and then added to a 7 ml
reaction mixture containing 4 ml SuperScript III RT buffer (10),
1 ml DTT (0.1 M), 1 ml RNaseOUT Recombinant RNase
inhibitor (40 U/ml; Invitrogen Corporation, USA) and 1 ml
SuperScript III M-MLV reverse transcriptase (200 U/ml). The
samples were mixed and incubated at 50uC for 60 min. Reactions
were terminated at 70uC for 15 min and the RT products were
stored at 220uC until further use.
Quantitative real-time RT-PCR assays were carried out using a
7700 Sequence Detector (Applied Biosystems, USA). GAPDH,
which has previously been used as a housekeeping gene in placenta
by severalinvestigators[59–61], was used as the housekeeping gene.
All the placental tissue samples were from the third trimester. There
was a positive correlation between GAPDH expression and the
expression of another commonly used housekeeping gene HPRT,
when studied in the same samples (Figure S4).
Steady-state mRNA levels of IGF2, H19, IGF2R and
housekeeping gene GAPDH were measured using gene-specific
primers and QuantiFast SYBR Green PCR Master Mix (Qiagen,
USA). The primer sequences were following: IGF2 Forward 59-
TCTGACCTCCGTGCCTA-39, IGF2 Reverse 59-TTGGGAT-
TGCAAGCGTTA-39, H19 Forward 59-AGAAGCGGGTCT-
GTTTCTTTA-39, H19 Reverse 59-TGGGTAGCACCATTT-
CTTTCA-39, IGF2R Forward 59-ACCTCAGCCGTGTGTC-
CTCT-39, IGF2R Reverse 59-CTCCTCTCCTTCTTGTA-
GAGCAA-39, GAPDH Forward 59-GAGTCAACGGATTTG-
GTCGT-39, and GAPDH Reverse 59-TTGATTTTGGAGG-
GATCTCG-39. PCR reactions were performed by mixing 1 mlo f
cDNA (50 ng/ml placenta, 25 ng/ml cord blood) with 24 mlo f
reaction mixture (12.5 ml QuantiFast SYBR Green PCR Master
Mix (2X), 2.5 ml forward primer (10 mM), 2.5 ml reverse primer
(10 mM), and 6.5 ml nuclease free dH2O) and amplified under the
following conditions: 95uC for 5 min, followed by 40 cycles of
95uC for 10 s and 60uC for 30 s. A melting curve analysis of the
PCR products was performed to verify their specificity and
identity. PCR products were also run on 2% agarose gels to
confirm the size of the amplified products. Relative gene
expression levels were obtained using the DDCT method [62].
Quantitative Analysis of IGF2 and H19 Imprinting Status
To avoid genomic DNA contamination during imprinting
analysis, PCR was done across an intron-exon boundary and the
cDNA products were gel-purified. The primers used for assaying
IGF2 imprinting were: primer 1, 592ATCGTTGAGGAG-
TGCTGTTTC239; primer 2, 592CGGGGATGCATAAAG-
TATGAG239; primer 3, 592CTTGGACTTTGAGTCAAA-
TTGG239; and primer 4, 592GGTCGTGCCAATTACATT-
TCA239 [32]. Heterozygosity of an ApaI polymorphism in exon 9
of IGF2 was ascertained by doing PCR with genomic DNA using
primers 3 and 4 across the ApaI site, and the PCR product was
digested with ApaI. Imprinting status was ascertained by doing
RT-PCR, using primers 1 and 2 in exons 8 and 9, respectively.
The cDNA PCR product, which is shorter than any possible
contaminating genomic DNA product because of intron splicing,
was electrophoresed and purified from a 2% agarose gel using the
QIAquick Gel Extraction Kit (Qiagen, USA) following the
manufacturers protocol. Hot-stop PCR was then done using
primers 3 and 4, with a-
32P dCTP added before the last cycle. The
PCR product was digested with ApaI and then separated on
denaturing 5% polyacrylamide gels and the intensity of the bands
(alleles) were quantified using a PhosphoImage Reader FLA 5000
(FUJIFILM Medical Systems USA, Inc.).
The primers used for assaying H19 imprinting were: H19-1, 59-
GGAGTTGTGGAGACGGCCTTGAGT-39; H19-2, 59-CCAG-
TCACCCGGCCCAGATGGAG-39; and H19-3, 59-CTTTA-
CAACCACTGCACTACCTGAC-39. Heterozygosity of an RsaI
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with genomic DNA using primers H19-1 and H19-2 across the
RsaI site, and the PCR product was digested with RsaI. Imprinting
status was ascertained by doing RT-PCR, using primers H19-3
and H19-2 in exons 4 and 5, respectively. The cDNA PCR
product, which is shorter than any possible contaminating
genomic DNA product because of intron splicing, was electro-
phoresed and purified from a 2% agarose gel using the QIAquick
Gel Extraction Kit (Qiagen, USA) following the manufacturers
protocol. Hot-stop PCR was then done using primers H19-1 and
H19-2, with a-
32P dCTP added before the last cycle. The PCR
product was digested with RsaI and then separated on denaturing
5% polyacrylamide gels and the intensity of the bands (alleles)
were quantified using a PhosphoImage Reader FLA 5000
(FUJIFILM Medical Systems USA, Inc.).
X-Inactivation Assay
X-chromosome inactivation ratios were assayed using previous-
ly published modifications of a methylation-sensitive PCR assay
[33,36,63–65]. We measured the methylation status of a CpG site
that is correlated with the expression of alleles at the X-linked,
highly polymorphic androgen receptor (AR) locus. Genomic DNA
from cord blood, cord and five sections of placenta was available
for 50 in vitro and 54 in vivo females who were heterozygous for AR
alleles that differed by more than one CAG repeat.
Genomic DNA from females who were heterozygous (informa-
tive) at the highly polymorphic (CAG)n repeat of the X-linked AR
gene was amplified after previous overnight digestion with HhaI
methyl-sensitive restriction endonuclease, with primers (AR1: 59-
AGAGGCCGCGAGCGCAGCAC-39 and AR2: 59-ACTCCAG-
GGCCGACTGCGGC-39), which flank the repeat and two HhaI
sites. We added a radiolabeled nucleotide for the last cycle of ‘hot-
stop’ PCR, rather than a single end-labeled primer, to increase the
signal. After 27 cycles at 94uC for 1 min, 68uC for 1 min, and
72uC for 1 min, 3 mCi a-
32P dCTP was added for one additional
cycle. PCR products were separated on denaturing 5% polyacryl-
amide gels and the intensity of the alleles was quantified by using
the PhosphoImage Reader FLA 5000 (FUJIFILM Medical
Systems USA, Inc.) [65]. As a way of quantifying the degree of
skewing, i.e., the degree to which the somatic cells of an individual
female deviated from a 1:1 ratio, the intensity of the upper allele
divided by the sum of the intensities of both alleles was computed
for each individual.
Statistical Analysis
The statistical significance of the methylation datasets repre-
senting the in vivo and in vitro group was examined using the
Wilcoxon Rank Sums Test. Data from the real time RT-PCR
experiments were analyzed using Student’s T-test. The number of
cells was estimated using the method described by Amos-Landgraf
et al. (2006) and Mclaren A (1972) [34,35]. P-values #0.05 were
considered significant.
Supporting Information
Figure S1 Intra-individual variation in IGF2 mRNA expression.
Steady-state IGF2 mRNA levels measured in five sections of
placenta in 12 individuals. IGF2 transcript levels vary by more
than an order of magnitude (n.b.: each unit on the vertical axis is a
power of 2) between individuals and between samples within some
individuals.
Found at: doi:10.1371/journal.pgen.1001033.s001 (0.05 MB TIF)
Figure S2 Lack of correlation between birth weight percentiles
and IGF2 or IGF2R mRNA levels in cord blood and placenta.
Birth weight percentiles in the in vitro and in vivo populations
plotted versus cord blood transcript levels of (A) IGF2, (B) IGF2R,
(C) IGF2/IGF2R, and placenta transcript levels of (D) IGF2, (E)
IGF2R, and (F) IGF2/IGF2R. Although average birth weight was
lower in the in vitro group, we found little correlation between birth
weight and IGF2 or IGF2R transcript levels (regression lines are
shown, straight and dashed lines for in vivo and in vitro populations,
respectively, and the maximum r
2of 0.2433 is found in (B), even
when birth weights were corrected for gestational age [Min, et al;
Oken, et al; Yarkoni, et al]. These findings are consistent with
previous observations from studies in human IUGR placentae
[43]. [Min SJ, Luke B, Min L, Misiunas R, Nugent C, et al. (2004)
Birth weight references for triplets. Am J Obstet Gynecol 191(3):
809-814. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW
(2003) A nearly continuous measure of birth weight for gestational
age using a United States national reference. BMC Pediatr 8(3): 6.
Yarkoni S, Reece EA, Holford T, O’Connor TZ, Hobbins JC
(1987) Estimated fetal weight in the evaluation of growth in twin
gestations: a prospective longitudinal study. Obstet Gynecol 69(4):
636-639.)
Found at: doi:10.1371/journal.pgen.1001033.s002 (0.46 MB TIF)
Figure S3 Correlation between IGF2R expression and P/M
methylation ratios in cord blood.
Found at: doi:10.1371/journal.pgen.1001033.s003 (0.06 MB TIF)
Figure S4 Positive correlation between GAPDH expression and
the expression of another commonly used housekeeping gene,
HPRT, when studied in the same placenta samples.
Found at: doi:10.1371/journal.pgen.1001033.s004 (0.12 MB TIF)
Table S1 Patient demographics.
Found at: doi:10.1371/journal.pgen.1001033.s005 (0.04 MB
DOC)
Table S2 Summary of assays used, number of individuals
studied, and tissues investigated.
Found at: doi:10.1371/journal.pgen.1001033.s006 (0.05 MB
DOC)
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